Stoke Therapeutics, Inc. (STOK) — closed signal from October 23, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 21, 2026.
Predicted vs. what happened
What happened
Reached 32% of the predicted growth at its peak, without hitting the target.
The thesis — published October 23, 2025
Stoke looks appealing after strong long-term results in Dravet syndrome. Recent updates said 95% of patients improved, and an analyst kept a Buy rating with a $35 target, lifting confidence. The price trend appears solid, momentum is positive, and there are signs that lots more people are buying than usual. Over the next 0-3 months, consider small buys on gentle dips and add if prices climb on strong trading, while staying cautious given biotech swings.
Primary drivers
- 3-year Dravet study showed strong patient benefits reported on 10-10
- Analyst reaffirmed Buy rating and $35 target, boosting investor mood
- Price trend and momentum look strong, signaling continued strength
- Upcoming trial updates and news could arrive soon and draw interest
How it played out
STOK: target missed after a 12.9% peak
On 2025-10-23, Lyra published a short-term STOK thesis at 33.08. It expected 40% growth to 46.31. The thesis pointed to strong long-term Dravet syndrome results, a reported 95% patient improvement figure, a reaffirmed Buy rating, positive momentum, unusual buying interest, and possible trial updates or news inside the window.
Inside the window, STOK rose but stayed below the target. The peak was 37.34 on 2026-01-07, a 12.9% gain. It never reached 46.31. By 2026-01-21, the stock ended at 29.50, below the publication price. The thesis partially played out on price strength, but missed its target.
What happened during the window
On 2025-12-16, Investor's Business Daily reported that Stoke had released third-quarter results on 2025-11-04. The article said revenue rose 117% year over year to $10.6 million, while the per-share loss widened to $0.65.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.